Patents by Inventor Robert Hofmeister

Robert Hofmeister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11965012
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: April 23, 2024
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20240117002
    Abstract: Provided herein are recombinant nucleic acids encoding a T cell receptor (TCR) fusion protein (TFP) and an interleukin-15 (IL-15) polypeptide and/or an interleukin-15 receptor alpha (IL-15R?) polypeptide, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 11, 2024
    Inventors: Robert TIGHE, Pooja ARORA, Robert HOFMEISTER, Dario GUTIERREZ, Derrick MCCARTHY, Michelle FLEURY
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11851491
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 26, 2023
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR AUTOIMMUNITY REGULATION
    Publication number: 20230338421
    Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including autoinmmune diseases.
    Type: Application
    Filed: January 8, 2021
    Publication date: October 26, 2023
    Inventors: Daniel GETTS, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Dario GUTIERREZ, Dana GILMORE
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20230235010
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 27, 2023
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230065936
    Abstract: Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)-expressing T cells. A ratio of CD4+ to CD8+ T cells in a sample from the human subject may have been determined before the administration of the plurality of anti-MSLN TFP-expressing T cells. The plurality of anti-MSLN TFP-expressing T cells may comprise a pre-determined ratio of CD4+ to CD8+ T cells.
    Type: Application
    Filed: April 8, 2022
    Publication date: March 2, 2023
    Inventors: Alfonso QUINTÁS-CARDAMA, Robert HOFMEISTER, Robert TIGHE
  • COMPOSITIONS AND METHODS FOR GAMMA DELTA TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20230069322
    Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified ?? T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 23, 2020
    Publication date: March 2, 2023
    Inventors: Jian DING, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Dario GUTIERREZ, Robert TIGHE, Julio GOMEZ RODRIGUEZ
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20220362295
    Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: April 22, 2020
    Publication date: November 17, 2022
    Inventors: Philippe KIEFFER-KWON, Ella LIBERZON, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Daniel GETTS
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20220298478
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 22, 2022
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11377638
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 5, 2022
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11242376
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: February 8, 2022
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210361704
    Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: March 8, 2019
    Publication date: November 25, 2021
    Inventors: Patrick Alexander BAEUERLE, Robert HOFMEISTER, Daniel GETTS, Philippe KIEFFER-KWON, Julie DONAGHEY
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS
    Publication number: 20210315933
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more MUC16 or IL 13R?2 or MSLN TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: July 26, 2019
    Publication date: October 14, 2021
    Inventors: Patrick Alexander Baeuerle, Robert Hofmeister, Daniel Getts, Vania Ashminova, Jian Ding
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210253666
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs) having specificity for more than one tumor cell associated antigen, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 30, 2019
    Publication date: August 19, 2021
    Inventors: Patrick Alexander Baeuerle, Robert Hofmeister, Jian Ding, Vania Ashminova, Michael Lofgren
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210206827
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 8, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • ENGINEERED T CELLS FOR THE TREATMENT OF CANCER
    Publication number: 20210187022
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 24, 2021
    Inventors: Daniel GETTS, Ekta PATEL, Patrick BAEUERLE, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11028142
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: June 8, 2021
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20210079057
    Abstract: Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 13, 2018
    Publication date: March 18, 2021
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20200362011
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 19, 2020
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER